Giles Gwinnett is a qualified journalist and has been a reporter for a number of regional newspapers and for a press agency. He was formerly a news analyst on the German team at Thomson Financial, now Thomson Reuters. He has a bachelor’s degree in English Literature and German and a master's in Film Studies.
However, the operating loss was widened in the three months to end June to $1.204mln
ZYN002 didn't meet its primary or secondary endpoint, the group told investors
"This capital provides the runway we need...," said Denis Corin
Friday Night is busily trying to tap into a growing market in Las Vegas, known as Sin City,..
Jefferies targets a punchy $25 for the shares, well over three times' the current price of at $7.30
"As a company with its roots in female health and wellness, we are committed to delivering breakthrough products...," the firm said
The regulator has granted breakthrough therapy designation for Imfinzi
Mystic Pharmaceuticals will get access to ValiRx's patented technology, including pre-clinical products
A look at some of the analyst comment on North America listed stocks on Monday
A look at some analyst views from around the City on Friday
A look at some analyst takes on a variety of stocks on Thursday
It is doubtful of a pick-up next year though suggests Cobham as a potential recovery play if new management’s plan is appreciated by investors.